Breaking Finance News

ValiRx PLC (LON:VAL) has been retained to Speculative Buy in a report by Beaufort Securities today.

Yesterday ValiRx PLC (LON:VAL) traded 0.37% higher at 6.88GBX. The company’s 50-day moving average is 7.47GBX and its two hundred day average is 8.87GBX. With the last stock price close down -23.59% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 208,164 shares of VAL changing hands under the typical 921,828

Beaufort Securities has retained ValiRx PLC (LON:VAL) to Speculative Buy in a statement released on 09/28/2016.

See Chart Below


ValiRx PLC has a with a one year low of 5.75GBX and a one year high of 29.80GBX VAL’s total market value is presently 0 GBX.

A total of 1 broker has issued a research note on the company. 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of 1.05GBX.

About ValiRx PLC (LON:VAL)

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *